To improve internal control and corporate governance, on 25 March 2021, the sixth meeting of the seventh session of the board of directors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. reviewed and approved the adjustments in the roles of members of the nomination committee of the Company (the ``Nomination Committee'') pursuant to the requirements of domestic laws, regulations and the listing rules of the STAR Market of the Shanghai Stock Exchange. Wang Hai Bo, chairman of the Nomination Committee will now be member of the Nomination Committee; Xu Qing, member of the Nomination Committee will now be chairman of the Nomination Committee.